Thymosin alpha-1 dosing: what published protocols describe
The numbers come from international trials. The decision still belongs to a clinician.
TL;DR
- Most published thymosin alpha-1 protocols use 1.6 mg subcutaneously twice weekly, drawn from the international Zadaxin label.
- Compounded thymosin alpha-1 is not FDA-approved. Any dosing is off-label and clinician-supervised.
- Loading phases, body-weight adjustments, and indication-specific tweaks are part of the conversation.
What it is
Thymosin alpha-1 is a 28-amino-acid peptide (in plain English: a small chain of building blocks the immune system uses as a signal). It is approved internationally as Zadaxin and is used for chronic hepatitis B and as an adjunct in some cancer protocols (Tuthill et al., Clin Lymphoma Myeloma Leuk, 2010). The compounded version available through 503A pharmacies in the United States is not FDA-approved.
How it works
Picture a quiet voice that walks the immune system through its checklist — show me the problem, send the right cell to it, and stand down when the work is done. Thymosin alpha-1 is that voice. It engages toll-like receptors (in plain English: protein switches on immune cells that flip on when something looks wrong) and helps T cells (a kind of immune cell) coordinate (Goldstein & Garaci, Expert Opin Biol Ther, 2012).
Who asks about it
People usually ask about dosing after deciding with a clinician that thymosin alpha-1 might fit a specific situation — recurrent infections, immune support during a chronic condition, recovery context. The dosing question matters because the published numbers come from international trials, not US labels.
What the published research says
The Zadaxin international label and most peer-reviewed protocols use 1.6 mg subcutaneously twice weekly, separated by three to four days. Hepatitis B trials run six to twelve months at this dose. Cancer adjunct studies use the same dose with longer durations and sometimes a daily loading phase (Tuthill et al., 2010; Goldstein & Garaci, 2012). Off-label use in the United States typically draws from this range.
What to know before considering it
Thymosin alpha-1 is generally well-tolerated in physician-supervised protocols. Reported reactions include injection-site irritation and mild flu-like symptoms in early doses. People on immunosuppressive therapy after organ transplant should not use it without specialist input — stimulating the immune system can complicate immunosuppression. Compounded thymosin alpha-1 is not FDA-approved.
The Halftime POV
A “standard” dose that comes from international trials is a starting point, not a prescription. Body size, condition, and concurrent medications all matter. The honest move: bring the published numbers to a clinician conversation, not the other way around.
Related reading:
- Thymosin alpha-1 research: where it has been studied
- Thymosin alpha-1 side effects and contraindications
- How thymosin alpha-1 signals the immune system: the mechanism
FAQ
Q: What is the typical thymosin alpha-1 dose? A: Most published protocols use 1.6 mg given subcutaneously twice weekly. The international Zadaxin label uses this dosing for chronic hepatitis B in adults. Clinician protocols for off-label use draw from the same range, with adjustments based on patient size, indication, and tolerance.
Q: How often is thymosin alpha-1 injected? A: Twice weekly is the most common schedule in the literature, separated by three to four days. Some protocols use daily dosing during an initial loading phase, then drop to twice weekly. A clinician sets the exact schedule.
Q: Is thymosin alpha-1 FDA-approved? A: No. Thymosin alpha-1 is approved internationally as Zadaxin in more than 30 countries, but it is not FDA-approved in the United States. Compounded thymosin alpha-1 is prepared by state-licensed 503A pharmacies and is not FDA-approved.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Tuthill C, et al. Thymosin alpha-1: an immune modulator. Clinical Lymphoma, Myeloma & Leukemia, 2010.
- Goldstein AL, Garaci E. Thymosin alpha-1: from bench to bedside. Expert Opinion on Biological Therapy, 2012.
